RT Journal Article
SR Electronic
T1 Severity of COVID-19 is inversely correlated with increased number counts of non-synonymous mutations in Tokyo
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.24.20235952
DO 10.1101/2020.11.24.20235952
A1 Abe, Kodai
A1 Kabe, Yasuaki
A1 Uchiyama, Susumu
A1 Iwasaki, Yuka W.
A1 Ishizu, Hirotsugu
A1 Uwamino, Yoshifumi
A1 Takenouchi, Toshiki
A1 Uno, Shunsuke
A1 Ishii, Makoto
A1 Murata, Mitsuru
A1 Hasegawa, Naoki
A1 Saya, Hideyuki
A1 Kitagawa, Yuko
A1 Fukunaga, Koichi
A1 Amagai, Masayuki
A1 Siomi, Haruhiko
A1 Suematsu, Makoto
A1 Kosaki, Kenjiro
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/24/2020.11.24.20235952.abstract
AB Background SARS-CoV-2 genome accumulates point mutations in a constant manner. Whether the accumulation of point mutations is correlated with milder manifestations of COVID-19 remains unknown.Methods We performed SARS-CoV-2 genome sequencing in 90 patients with COVID-19 infection treated at a tertiary medical center in Tokyo between March and August 2020. The possible association between disease severity and viral haplotype was then assessed by counting the number of mutations in addition to performing phylogenic tree analysis, comparative amino acid sequence analysis among β-coronaviruses, and mathematical prediction of the functional relevance of amino acid substitutions.Results The number of non-synonymous mutations was inversely correlated with COVID-19 severity, as defined by requiring oxygen supplementation. Phylogenic tree analysis identified two predominant groups which were separated by a set of 6 single nucleotide substitutions, including four leading to non-synonymous amino acid substitutions. Among those four, Pro108Ser in 3 chymotrypsin-like protease (3CLpro) and Pro151Leu in nucleocapsid protein occurred at conserved locations and were predicted to be deleterious. Patients with Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein had a lower odds ratio for developing hypoxia requiring supplemental oxygen (odds ratio of 0.24 [95% confidence interval of 0.07-0.88, P-value = 0.032]) after adjustments for age and sex, compared with patients lacking this haplotype in Clade 20B.Conclusion Viral genome sequencing in 90 patients treated in the Tokyo Metropolitan area showed that the accumulation of point mutations, including Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein, was inversely correlated with COVID-19 severity. Further in vitro research is awaited.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Keio Gijuku Academic Development Funds and by AMED under Grant Number JP20he0622043.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the Institutional Review Board of Keio University Hospital (approval number: 20200062)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe downloaded the full nucleotide sequences of the SARS-CoV-2 genomes from the GISAID database (https://www.gisaid.org/). A table of the contributors is available in the Supplementary Table 5. We have uploaded the full nucleotide sequences of our cohort to the GISAID database.